Replies to post #425036 on Anavex Life Sciences Corp (AVXL)

[12x]

As long as there is no endpoint measure changes as last two p2b/3 TLR announcements, my guess the chance of Excellence “FDA accepted” success is high as the company boosted excellence n from 2x to 3x Avatar.

In terms of AD, it took Lily 1.5 year to publish the p2b paper. The just published A3-71 paper was announced in January 2022. I don’t see how will see the AD p2b/3 published this year at all. The Excellence TLR is all what we are going to get this year IMO.

[Schmiggins]

Is there another Anavex board worth looking at? Post a link, if so. Thanks.